FDA Approves Lisraya as First Oral Therapy for Dermatomyositis
The FDA approved Priovant Therapeutics’ Lisraya (brepocitinib), a once-daily oral TYK2/JAK1 inhibitor, for adult dermatomyositis, making it the first oral, targeted therapy approved for the disease and validating the pivotal VALOR trial’s disease-activity and…
